80 results
Page 3 of 4
8-K
EX-99.1
bge9fhb7l9jksqpyv
21 Jun 21
Entry into a Material Definitive Agreement
4:46pm
8-K
EX-99.1
8oelm8nio
14 Jun 21
Cassava Sciences Announces the Appointment of
4:14pm
8-K
EX-99.1
jw2pqjzt
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-99.1
pgs686x0
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-99.1
11l6r07ztnky0 rgb
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.2
c5ukvjna0ok97jhnqjqn
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
424B5
iaeomykro16v24eajp
12 Feb 21
Prospectus supplement for primary offering
12:00am
S-3ASR
jvuch651nq 9c
10 Feb 21
Automatic shelf registration
6:04am
8-K
EX-99.2
1e3o9uaypt uacpkfp
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
6dq8us 2xtfk7xho
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
424B5
cla7qru4qxn
16 Nov 20
Prospectus supplement for primary offering
12:21pm
8-K
EX-99.1
mwu1t1 jaoq44m
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.2
6hk2f04im j8h
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
424B5
w5yjubnu f9li2q6jf
12 Nov 20
Prospectus supplement for primary offering
4:57pm
8-K
EX-99.1
dnzi7i7x96yk4ho
9 Nov 20
Cassava Sciences Reports Third Quarter 2020 Financial Results
8:30am
8-K
EX-99.1
36wdfd7vy5
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
5sk5ill
14 Sep 20
Regulation FD Disclosure
4:01pm